Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.

摘要: Histone deacetylases (HDACs) enzymes, which affect the acetylation status of histones and other important cellular proteins, have been recognized as potentially useful therapeutic targets for a broad range human disorders. Emerging studies demonstrated that different types HDAC inhibitors show beneficial effects in various experimental models neurological enzymes comprise large family with18 currently identified humans. Hence, an question inhibitor therapeutics is enzyme(s) is/are amelioration disease phenotypes, it has become clear individual play biological roles brain. This review will discuss evidence supporting involvement HDAC1 HDAC3 polyglutamine disorders, including Huntington’s disease, use HDAC1- HDAC3-selective intervention these Further, while are known alter chromatin structure resulting changes gene transcription, understanding exact mechanisms responsible preclinical efficacy compounds remains challenge. The potential chromatin-related non-chromatin-related action selective also be discussed.